Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.

AlloVir, a US-based cell therapy developer based on research at Baylor College Of Medicine, filed for a $100m initial public offering on the Nasdaq Global Market on Monday. Founded in 2013, AlloVir is working on cell therapies generated from healthy donors that are designed to restore natural immunity in patients who suffer from T cell…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.